Bayer HealthCare and Maxygen (MAXY) Enter Hematology Agreement
More News related to MAXY
- Maxygen (MAXY) Receives $3.4 Million Government Grant to Develop Vaccine Discovery Technology
- Maxygen Receives $3.4 Million Government Grant to Develop Vaccine Discovery Technology
- Maxygen (MAXY) Tops Q2 EPS by 2c; Announces Resignation of Chief Medical Officer
- Maxygen Reports Second Quarter 2008 Financial Results
- Maxygen Second Quarter 2008 Financial Results Conference Call Notice
More News related to Mergers and Acquisitions
- Greater Atlantic Financial (GAFC) Shareholders Approve Merger with Summit Financial (SMMF)
- Ladish (LDSH) Completes Merger with Chen-Tech Industries; Deal Expected to be Accretive to '08 Earnings
- Altria (MO) Calls Reports of UST (UST) Bid "Pure Speculation"
- EZCORP (EZPW) Acquires Eleven Nevada Pawnshops For A Total Purchase Price of $34.5 Million
- Rick's Cabaret (RICK) Completes Purchase of Scores-Las Vegas Nightclub, with Renegotiated Terms
Bayer HealthCare announced the acquisition of Maxygen's (NASDAQ: MAXY) hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in the third quarter of 2008.
The total transaction is valued at $90 million upfront with a final, potential milestone payment of $30 million. This agreement also includes a license to use Maxygen’s MolecularBreedin technology, a novel research platform, for exploiting gene targets.
Related Categories
FDAMergers and Acquisitions
Stocks Mentioned
-0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
